Burnout in resident physicians

BJMO - volume 17, issue 3, may 2023

D. Schrijvers MD, PhD


Burnout is an important consequence of work-related stress. It is observed in 15–40% of resident physicians and has an important influence on their wellbeing, their professional career, and their patient-doctor relationship. Different interventions at the organisational, interpersonal and personal levels can be performed to prevent the development of burnout.

(BELG J MED ONCOL 2023;17(3):85–7)

Read more

Audits in medical oncology

BJMO - volume 17, issue 1, january 2023

D. Schrijvers MD, PhD


The quality of oncological care can be ensured by different means, such as graduate and postgraduate education, guidelines, quality labels and audits. Audits in medical oncology departments are not routinely performed and are only used in case of problems. In this article, the introduction of audits in the medical oncology department is advocated, and a strategy to implement this quality improving tool is proposed.

(BELG J MED ONCOL 2023;17(1):19–26)

Read more

Relationship between volume and outcome in lung cancer

BJMO - volume 16, issue 2, march 2022

D. Verhoeven MD, PhD, P. Bogaerts MD, P. Bernaerts MD, W. Demey MD


The use of survival data to compare hospitals remains controversial. Recently three studies could not find an association between outcome and volume. More important than the volume of surgery seems to be the concentration of oncological care in centres with multidisciplinary teams around the patient. A framework for implementing Value-Based health care has to be defined, measuring outcomes that matter to patients and cost.

(BELG J MED ONCOL 2022;16(2):70–3)

Read more

Moving forward together: The power of collaboration via networks

BJMO - 2022, issue 1, february 2022

M. Aapro MD

(BELG J MED ONCOL 2022;16(1):33-6)

Read more

Palliative Care: A Shift in Paradigm

BJMO - volume 15, issue 6, october 2021

C. Langenaeken MD, G. Huysmans MD


The integration of palliative care (PC) in standard oncological care (SOC) has become ‘state-of-the art’. Its benefits have increasingly been appreciated and extensively studied, and guidelines have been developed to achieve this goal. However, an integrated, patient-centred approach also implies detecting patients care needs at an earlier stage and defining PC in a different way, i.e. based on care needs instead of life expectancy only. The ‘Palliative Care Indicator Tool’ PICT is instrumental in identifying the palliative patient and distinguishing different levels of needs in the palliative population. The status of ‘palliative patient’, access to PC benefits and facilities and the organisation and reimbursement of PC services should be based on care needs instead of life expectancy. Palliative care for every palliative patient requires an educated workforce, particularly with regard to communication skills, and the presence of a multidisciplinary team. Discussing goals of care (GoC), advance care planning (ACP) and end-of-life decisions (ELD) should be the basis for ‘negotiated care’.

(BELG J MED ONCOL 2021;15(6):315-20)

Read more

The Belgian practice and attitudes towards introducing genomics in clinical oncology

BJMO - volume 15, issue 4, june 2021

M. Van den Bulcke PhD, W. Van hoof PhD, E. Van Valckenborgh PhD, Ir A. Hébrant PhD, G. Raicevic PhD, K. Van Assche PhD


For most people, being in good health represents the most important factor to wellbeing. While environmental elements such as physical, chemical, biological, social and psychosocial factors in the environment are key for a person’s wellbeing, also the genome of the individual and its interaction with the environment play an important role. In this paper, we will focus on attitudes towards genomics in the field of personalised medicine in oncology. We will document opinions encountered by patients and citizens on sharing health-related information for various purposes (e.g., research, cost-effectiveness, patient support) aiming to maximise the benefits for cancer patients. We will discuss ethical and legal considerations to be taken into account at the Belgian level to provide a secure, transparent framework for the use of genomics in the healthcare system.

(BELG J MED ONCOL 2021;15(4):177-85)

Read more

Role of the pharmacist in oncology: pharmaceutical care for patients treated with oral anticancer drugs

BJMO - volume 14, issue 7, november 2020

I. Kenis PharmD, L-M Kinnaer PhD, PharmD, T. Van Nieuwenhuyse PharmD, V. Foulon PhD, PharmD


Over the last decades, the development and use of oral anticancer drugs has increased substantially. Although oral anticancer drugs are associated with numerous advantages, they also entail important challenges for patients and for healthcare professionals. In contrast to intravenous chemotherapy and immunotherapy, the administration of oral anticancer drugs takes place at the patients’ home. This implies a greater autonomy and responsibility for patients in their own care. To achieve an adequate level of self-management in patients and to provide effective self-management support by health care professionals, an interdisciplinary approach is crucial. However, the (potential) contribution of hospital pharmacists and community pharmacists to support adequate patient self-management in oncology, has not been described in policy documents (EPAAC, ESMO, ASCO, BeNCP) and is rather unknown for most health care professionals and patients. Therefore, this review aims to summarise the evidence on the role of the pharmacist, both in the hospital and in primary care, in the care process for patients treated with oral anticancer drugs and to discuss future opportunities for the evolvement of this role.

Different approaches and interventions, led by a hospital pharmacist, have been described and tested to improve quality and safety of the care for patients treated with oral anticancer drugs. Several of these interventions resulted in significant improvements in adherence, safety and other patient outcomes, which shows the added value of the involvement of a hospital pharmacist in the care for patients treated with oral anticancer drugs. However, the impact of interventions performed by a community pharmacist on outcomes in patients treated with oral anticancer drugs remains unclear.

Based on the evidence in literature, this article further describes the potential roles of the hospital pharmacist and community pharmacist in the total care process for patients treated with oral anticancer drugs. This ranges from checking doses and regimens and evaluation of potential drug interactions over dispensing and patient counselling to assessment and management of toxicity and adherence. Based on what we found in literature, we can conclude that involvement of both the hospital and the community pharmacist seems crucial to obtain an adequately individualised treatment and monitoring plan, with respect to comorbidities and concomitant medication.

(BELG J MED ONCOL 2020;14(7):355-63)

Read more